NASDAQ:MTEM

Molecular Templates Stock Forecast, Price & News

$7.00
-0.30 (-4.11 %)
(As of 07/30/2021 12:00 AM ET)
Add
Compare
Today's Range
$6.91
$7.27
50-Day Range
$6.80
$9.07
52-Week Range
$6.41
$15.19
Volume145,972 shs
Average Volume185,745 shs
Market Capitalization$392.70 million
P/E RatioN/A
Dividend YieldN/A
Beta1.31
30 days | 90 days | 365 days | Advanced Chart
Receive MTEM News and Ratings via Email

Sign-up to receive the latest news and ratings for Molecular Templates and its competitors with MarketBeat's FREE daily newsletter.


Molecular Templates logo

About Molecular Templates

Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other diseases. Its proprietary drug platform technology is engineered toxin bodies (ETBs). The company's lead drug candidate is MT-3724 that is in a Phase II clinical trial for the treatment of relapsed and refractory diffuse large B-cell lymphoma; and Phase II clinical trial for treating non-Hodgkin's lymphoma. It also develops MT-4019, engineered toxin body targeting CD38; TAK-169 targeting CD38 is in Phase I clinical trial; MT-5111 targeting HER2 is in Phase I clinical trial; and MT-6402 with antigen seeding targeting PD-L1. The company has an agreement with Takeda Pharmaceutical Company Limited to develop CD38-targeted engineered toxin bodies for the treatment of patients with diseases, such as multiple myeloma; and a strategic research collaboration with Vertex Pharmaceuticals Incorporated to discover and develop novel targeted biologic therapies for applications outside of oncology; and Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. is headquartered in Austin, Texas.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous

Social Links


MarketRank

Overall MarketRank

2.36 out of 5 stars

Medical Sector

126th out of 2,221 stocks

Pharmaceutical Preparations Industry

62nd out of 869 stocks

Analyst Opinion: 3.4Community Rank: 3.4Dividend Strength: 0.0Insider Behavior: 5.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Molecular Templates (NASDAQ:MTEM) Frequently Asked Questions

Is Molecular Templates a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Molecular Templates in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Molecular Templates stock.
View analyst ratings for Molecular Templates
or view top-rated stocks.

What stocks does MarketBeat like better than Molecular Templates?

Wall Street analysts have given Molecular Templates a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Molecular Templates wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Molecular Templates' next earnings date?

Molecular Templates is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Molecular Templates
.

How were Molecular Templates' earnings last quarter?

Molecular Templates, Inc. (NASDAQ:MTEM) issued its quarterly earnings data on Thursday, May, 13th. The biotechnology company reported ($0.51) EPS for the quarter, missing the consensus estimate of $0.31 by $0.82. The biotechnology company earned $3.22 million during the quarter, compared to analysts' expectations of $29.66 million. Molecular Templates had a negative net margin of 611.90% and a negative trailing twelve-month return on equity of 138.03%.
View Molecular Templates' earnings history
.

How has Molecular Templates' stock price been impacted by COVID-19?

Molecular Templates' stock was trading at $13.22 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, MTEM stock has decreased by 47.0% and is now trading at $7.00.
View which stocks have been most impacted by COVID-19
.

When did Molecular Templates' stock split? How did Molecular Templates' stock split work?

Molecular Templates shares reverse split on Wednesday, August 2nd 2017. The 1-11 reverse split was announced on Tuesday, August 1st 2017. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, August 1st 2017. An investor that had 100 shares of Molecular Templates stock prior to the reverse split would have 9 shares after the split.

What price target have analysts set for MTEM?

4 Wall Street analysts have issued twelve-month price objectives for Molecular Templates' shares. Their forecasts range from $12.00 to $20.00. On average, they anticipate Molecular Templates' share price to reach $14.50 in the next year. This suggests a possible upside of 107.1% from the stock's current price.
View analysts' price targets for Molecular Templates
or view top-rated stocks among Wall Street analysts.

Who are Molecular Templates' key executives?

Molecular Templates' management team includes the following people:
  • Dr. Eric E. Poma, CEO, Chief Scientific Officer & Director (Age 49, Pay $820.9k)
  • Ms. Jason S Kim, Pres & COO (Age 46, Pay $590.25k)
  • Dr. Roger J. Waltzman, Chief Medical Officer (Age 53, Pay $572.91k)
  • Mr. Adam D. Cutler B.A., CFO, Treasurer & Sec. (Age 46)
  • Mr. Kurt Elster, Exec. VP of Corp. Devel. (Age 54)
  • Dr. Jack Higgins Ph.D., Exec. VP of Operations & Head of Manufacturing (Age 41)
  • Dr. Erin Willert Ph.D., Exec. VP of R&D (Age 39)
  • Dr. Jen-Sing Liu Ph.D., Exec. VP of Manufacturing (Age 58)
  • Dr. Nenad Sarapa M.D., M.S., Sr. VP of Clinical Devel.
  • Sean McLennan, Sr. VP of Fin. & Controller

Who are some of Molecular Templates' key competitors?

What other stocks do shareholders of Molecular Templates own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Molecular Templates investors own include ZIOPHARM Oncology (ZIOP), Novavax (NVAX), Gilead Sciences (GILD), TG Therapeutics (TGTX), CEL-SCI (CVM), Pfizer (PFE), Synergy Pharmaceuticals (SGYP), Amarin (AMRN), Corbus Pharmaceuticals (CRBP) and Exelixis (EXEL).

What is Molecular Templates' stock symbol?

Molecular Templates trades on the NASDAQ under the ticker symbol "MTEM."

Who are Molecular Templates' major shareholders?

Molecular Templates' stock is owned by many different institutional and retail investors. Top institutional investors include Alliancebernstein L.P. (0.07%). Company insiders that own Molecular Templates stock include Jason S Kim, Kevin M Lalande, Longitude Capital Partners Iii, Scott D Morenstein and Target N V Biotech.
View institutional ownership trends for Molecular Templates
.

Which major investors are buying Molecular Templates stock?

MTEM stock was bought by a variety of institutional investors in the last quarter, including Alliancebernstein L.P.. Company insiders that have bought Molecular Templates stock in the last two years include Longitude Capital Partners Iii, Scott D Morenstein, and Target N V Biotech.
View insider buying and selling activity for Molecular Templates
or or view top insider-buying stocks.

How do I buy shares of Molecular Templates?

Shares of MTEM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Molecular Templates' stock price today?

One share of MTEM stock can currently be purchased for approximately $7.00.

How much money does Molecular Templates make?

Molecular Templates has a market capitalization of $392.70 million and generates $18.84 million in revenue each year. The biotechnology company earns $-104,920,000.00 in net income (profit) each year or ($2.13) on an earnings per share basis.

How many employees does Molecular Templates have?

Molecular Templates employs 247 workers across the globe.

When was Molecular Templates founded?

Molecular Templates was founded in 2009.

What is Molecular Templates' official website?

The official website for Molecular Templates is www.mtem.com.

Where are Molecular Templates' headquarters?

Molecular Templates is headquartered at 9301 AMBERGLEN BLVD. SUITE 100, AUSTIN TX, 78729.

How can I contact Molecular Templates?

Molecular Templates' mailing address is 9301 AMBERGLEN BLVD. SUITE 100, AUSTIN TX, 78729. The biotechnology company can be reached via phone at (512) 869-1555 or via email at [email protected]


This page was last updated on 7/31/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.